Sort
10,766 grants matching “checkpoint inhibitor”
Optimization of Tannic Acid Lipid Nanoparticles for a Therapeutic mRNA Vaccine Against Melanoma
$226,495Owen S Fenton · Univ Of North Carolina Chapel Hill · R21 · FY2023 · EB
RNA methylation as a novel effector of SETD2 in kidney cancer
$226,364Keith D Robertson · Mayo Clinic Rochester · R21 · FY2024 · CA
Optimization of Tannic Acid Lipid Nanoparticles for a Therapeutic mRNA Vaccine Against Melanoma
$226,293Owen S Fenton · Univ Of North Carolina Chapel Hill · R21 · FY2024 · EB
Removing sialic acid ligands of CD28 to enhance T cell cancer immunotherapy
$226,250James C. Paulson · Scripps Research Institute, The · R21 · FY2023 · AI
Investigating the non-cell autonomous immune effects of mutant p53 in pancreatic cancer
$225,979Despina Siolas · New York University School Of Medicine · K08 · FY2020 · CA
Investigating the non-cell autonomous immune effects of mutant p53 in pancreatic cancer
$225,979Despina Siolas · New York University School Of Medicine · K08 · FY2019 · CA
Investigating the non-cell autonomous immune effects of mutant p53 in pancreatic cancer
$225,979Despina Siolas · Weill Medical Coll Of Cornell Univ · K08 · FY2021 · CA
Investigating the non-cell autonomous immune effects of mutant p53 in pancreatic cancer
$225,979Despina Siolas · Weill Medical Coll Of Cornell Univ · K08 · FY2022 · CA
Investigating the non-cell autonomous immune effects of mutant p53 in pancreatic cancer
$225,979Despina Siolas · Weill Medical Coll Of Cornell Univ · K08 · FY2023 · CA
PD-L1 inhibition promotes type I interferon responses, enhancing chemotherapy-induced cytotoxicity in cancer cells
$225,803Hyeonjoo Cheon · Cleveland Clinic Lerner Com-Cwru · R21 · FY2021 · CA
The impact of genetic diversity among Akkermansia strains on the effectivenes of immune checkpoint inhibitors in cancer immunotherapies
$225,803Raphael H. Valdivia · Duke University · R21 · FY2021 · CA
scFvPD1-FLT3 CAR T Cells for the Treatment of Relapsed Acute Myeloid Leukemia
$225,765Jianhua Yu · Beckman Research Institute/City Of Hope · R21 · FY2019 · CA
RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS
$225,703St. Jude Children'S Research Hospital · R01 · FY2002 · CA
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy
$225,703John Tanner Wilson · Vanderbilt University · R01 · FY2025 · CA
Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs
$225,566Walter J Storkus · Roswell Park Cancer Institute Corp · P01 · FY2024 · CA
Study of Anti-Survival signals in NF1
$225,443Changyan Chen · Northeastern University · R01 · FY2017 · CA
CELL CYCLE REGULATION DURING SPERMATOGENESIS
$225,225University Of Tennessee Knoxville · R01 · FY2001 · HD
CELL CYCLE REGULATION DURING SPERMATOGENESIS
$225,225University Of Tennessee Knoxville · R01 · FY2002 · HD
Effect of oncolytic herpesvirus on the tumor microenvironment
$225,148Paul Rider · Lsu Health Sciences Center · P20 · FY2020 · GM
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
$225,068Edward B Garon · University Of California Los Angeles · R01 · FY2025 · CA
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
$225,068Edward B Garon · University Of California Los Angeles · R01 · FY2024 · CA
Targeted inhibition of metabolic pathways to enhance radiopharmaceutical therapy
$225,066Sangeeta Ray · Johns Hopkins University · R21 · FY2023 · CA
RAPAMYCIN BLOCKADE OF PROTEIN PHOSPHATASE SIGNALING
$225,025University Of Virginia Charlottesville · R01 · FY2005 · CA
Development of a pipeline tool to predict immunogenicity of cancer neo-epitopes
$225,000Alessandro Sette · La Jolla Institute For Immunology · R21 · FY2019 · AI
New anti-glioblastoma metabolic compounds with high potential for Blood Brain Barrier penetration
$225,000Krzysztof Reiss · Waypath Pharma Llc · R41 · FY2022 · CA